Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →Coforge Ltd — Q2 FY25
Coforge delivered an exceptionally strong Q2 FY25, with consolidated revenue of $369.4M, up 26.8% sequentially in USD terms, driven by broad-based growth across all verticals and geographies.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Coforge delivered an exceptionally strong Q2 FY25, with consolidated revenue of $369.4M, up 26.8% sequentially in USD terms, driven by broad-based growth across all verticals and geographies. The organic business grew 6.3% QoQ, while Cigniti added 6.1% QoQ, validating management's earlier assertions on demand recovery and synergy realization. EBITDA margin expanded 55bps YoY to 15.8%, with Cigniti's standalone margin jumping 360bps QoQ to 16.2%. Order intake surged to $516M, and the 12-month signed order book rose 40% YoY to $1.3B. Management raised Cigniti's FY25 EBITDA margin target to 18%+ (from 16.5%). Key risks include ESOP cost headwinds of ~120bps incremental in H2 and potential furlough impact in Q3.
कोफोर्ज ने दूसरी तिमाही (Q2 FY25) में बहुत अच्छा प्रदर्शन किया। कंपनी की कुल आय 369.4 मिलियन डॉलर रही, जो पिछली तिमाही से 26.8% बढ़ी। यह वृद्धि सभी क्षेत्रों और देशों में हुई। कंपनी के अपने कारोबार में 6.3% और सिग्निटी में 6.1% की बढ़ोतरी हुई। मुनाफा (EBITDA) 15.8% रहा, जो पिछले साल से 0.55% अधिक है। सिग्निटी का मुनाफा 16.2% पर पहुंच गया। नए ऑर्डर 516 मिलियन डॉलर मिले और 12 महीने के पक्के ऑर्डर 1.3 बिलियन डॉलर हो गए। कंपनी ने सिग्निटी के मुनाफे का लक्ष्य 18% कर दिया। खतरे: कर्मचारियों को शेयर देने का खर्च बढ़ेगा और तीसरी तिमाही में काम कम हो सकता है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
ESOP cost headwind impacting margins
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Sequential Revenue Growth (Consolidated)
26.8%
+26.8% QoQ
Consolidated revenue grew 26.8% sequentially in USD terms, crossing $1.5B annualized run rate.
Order Intake
$516M
+72% QoQ
Order intake more than doubled sequentially, including $67M from Cigniti, with three large deals signed.
12-Month Signed Order Book
$1.3B
+40% YoY
The 12-month signed order book jumped 40% year-over-year, indicating strong forward visibility.
Cigniti Standalone EBITDA Margin
16.2%
+360bps QoQ
Cigniti's EBITDA margin expanded 360bps sequentially to 16.2%, with a new target of 18%+ by Q4.
What Changed vs Last Quarter
NEW
Cigniti standalone EBITDA margin target raised to 18%+ by Q4 FY25
Management now expects Cigniti's EBITDA margin to exceed 18% by the end of the fiscal year, up from the earlier target of 16.5%.
NEW
Medium-term revenue target of $2B with concurrent margin expansion
Management reiterated its medium-term guidance of reaching $2B in revenue while delivering material EBITDA margin expansion.
NEW
ESOP cost headwind of ~120bps incremental in Q3 and Q4
CFO guided that incremental ESOP cost will be ~120bps per quarter for the next two quarters, with total ESOP cost of ~180-200bps.
DROPPED
50 bps adjusted EBITDA margin expansion for FY25
Management reaffirms guidance of 50 bps improvement in adjusted EBITDA margin for the full fiscal year, with H1 margins expected to be 50 bps higher than H1 FY24.
DROPPED
Cigniti EBITDA margin to exceed 16% from Q2 onwards
CFO guided that Cigniti's EBITDA margin will be 16%+ in Q2-Q4 FY25, up from 12.6% in Q1, driven by operational improvements and no further exceptional items.
DROPPED
Cigniti revenue growth to outpace Coforge
CEO stated that Cigniti will grow faster than Coforge in coming quarters, supported by new verticals and cross-sell initiatives.
DROPPED
Net cash position by end of FY25
CFO expects the company to become net cash by fiscal year-end, aided by QIP proceeds and debt repayment.
NEW RISK
ESOP cost headwind impacting margins
Incremental ESOP cost of ~120bps per quarter in H2 FY25 will pressure reported EBITDA margins.
NEW RISK
Furloughs in Q3 could impact sequential growth
Management expects normal furloughs in Q3, which could temper the strong sequential growth trajectory.
NEW RISK
GCC deal revenue durability risk
Some GCC deals have a build-operate-transfer structure, leading to potential revenue cliff after the initial mandate period.
NEW RISK
Integration and past liability risks from Cigniti
While management expects no further past liabilities, integration expenses may persist for a couple of quarters.
RISK GONE
Temporary blip in top banking clients may persist
Revenue from top 5 clients declined due to normalization in banking; if macro uncertainty delays program transitions, growth could be slower than expected.
RISK GONE
Wage hike impact on margins in Q2
Wage hikes effective July 1 will depress margins by 130-150 bps in Q2, though management expects efficiencies to offset partially.
RISK GONE
Cigniti integration and merger execution risk
Merger process may take 9-12 months; any delays or cultural friction could impact expected synergies and margin expansion.
RISK GONE
GenAI disruption in testing services
Analyst raised concern that GenAI could deflate volumes in testing; management downplayed risk but acknowledged functional testing may be impacted.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q3 FY24
Management reaffirms guidance of 50 bps improvement in adjusted EBITDA margin for the full fiscal year, with H1 margins expected to be 50 bps higher than H1 FY24.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Management expects to deliver within the annual guidance range of 13%-16% organic constant currency revenue growth, likely near the lower end.
Mentioned in Q1 FY25, Q4 FY24
Analyst raised concern that GenAI could deflate volumes in testing; management downplayed risk but acknowledged functional testing may be impacted.
Mentioned in Q1 FY24, Q4 FY24
New large deals, especially in new accounts, come with lower initial margins, which could pressure overall profitability.
Mentioned in Q1 FY25, Q4 FY24
CFO expects the company to become net cash by fiscal year-end, aided by QIP proceeds and debt repayment.
Fast read
Guidance and risk preview
Management now expects Cigniti's EBITDA margin to exceed 18% by the end of the fiscal year, up from the earlier target of 16.5%.
Incremental ESOP cost of ~120bps per quarter in H2 FY25 will pressure reported EBITDA margins.
View Risks →